Investors Purchase Large Volume of Call Options on Roivant Sciences (NASDAQ:ROIV)

Roivant Sciences Ltd. (NASDAQ:ROIV) was the target of some unusual options trading on Friday. Stock investors bought 32,948 call options on the company. This is an increase of 1,371% compared to the typical volume of 2,240 call options.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Roivant Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $17.93.

Roivant Sciences Trading Up 2.4 %

ROIV stock opened at $11.15 on Friday. The stock has a market cap of $8.12 billion, a P/E ratio of 1.97 and a beta of 1.27. The stock’s fifty day simple moving average is $11.79 and its two-hundred day simple moving average is $11.59. Roivant Sciences has a 1-year low of $9.69 and a 1-year high of $13.06.

Insider Activity at Roivant Sciences

In other news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was acquired at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the transaction, the director now directly owns 96,650,341 shares of the company’s stock, valued at approximately $1,933,006,820. This represents a 21.11 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Eric Venker sold 100,000 shares of the business’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $11.65, for a total value of $1,165,000.00. Following the sale, the chief operating officer now directly owns 617,470 shares of the company’s stock, valued at $7,193,525.50. This represents a 13.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,942,629 shares of company stock valued at $23,071,486 in the last three months. Corporate insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. TOMS Capital Investment Management LP bought a new position in Roivant Sciences during the third quarter valued at $46,333,000. Rubric Capital Management LP grew its stake in shares of Roivant Sciences by 15.0% during the 2nd quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock worth $243,110,000 after acquiring an additional 3,000,000 shares during the period. Troluce Capital Advisors LLC purchased a new stake in Roivant Sciences in the 2nd quarter worth about $31,182,000. FMR LLC lifted its holdings in Roivant Sciences by 5.6% during the third quarter. FMR LLC now owns 49,145,056 shares of the company’s stock valued at $567,134,000 after purchasing an additional 2,593,910 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Roivant Sciences by 23.2% during the third quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock worth $89,400,000 after purchasing an additional 1,460,205 shares during the period. 64.76% of the stock is owned by institutional investors.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.